{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T03:09:18Z","timestamp":1792638558181,"version":"4.5.0"},"reference-count":200,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T00:00:00Z","timestamp":1741046400000},"content-version":"vor","delay-in-days":31,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Many cancer treatments can lead to reduced levels of sex hormones, which in turn may cause vasomotor symptoms (VMS) such as hot flashes. These symptoms are associated with impaired quality of life, as well as suboptimal tolerability of and adherence to cancer treatment. Hormone therapy, performed by increasing estradiol or testosterone levels, is the gold standard for treatment of VMS. However, this approach is generally contraindicated in patients with hormone-sensitive cancers. Nonhormone agents with low to moderate efficacy in controlling VMS are available, but their use may be limited by side effects and tolerability. In this narrative review, the approach to VMS in cancer patients will be discussed. The evidence for various treatment options, including novel agents such as fezolinetant that target the hypothalamic thermoregulatory pathway, will be evaluated. Finally, special considerations in different patient populations based on cancer types (eg, breast, prostate) and age groups (eg, older adults) will be explored.<\/jats:p>","DOI":"10.1093\/oncolo\/oyaf002","type":"journal-article","created":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T00:40:26Z","timestamp":1741135226000},"source":"Crossref","is-referenced-by-count":16,"title":["Management of vasomotor symptoms in cancer patients"],"prefix":"10.1093","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9594-8467","authenticated-orcid":false,"given":"Ling","family":"Zhu","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Singapore General Hospital , Singapore 169856"},{"name":"Division of Endocrinology, Diabetes and Hypertension, Department of Medicine, Brigham and Women\u2019s Hospital , Boston, MA 02115 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tammy T","family":"Hshieh","sequence":"additional","affiliation":[{"name":"Division of Aging, Department of Medicine, Brigham and Women\u2019s Hospital , Boston, MA 02115 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara K","family":"Iyer","sequence":"additional","affiliation":[{"name":"Menopause and Midlife Clinic, Division of Women\u2019s Health, Department of Medicine, Brigham and Women\u2019s Hospital , Boston, MA 02215 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia K","family":"Morgans","sequence":"additional","affiliation":[{"name":"Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute , Boston, MA 02215 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3600-2628","authenticated-orcid":false,"given":"Ole-Petter R","family":"Hamnvik","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes and Hypertension, Department of Medicine, Brigham and Women\u2019s Hospital , Boston, MA 02115 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,3,4]]},"reference":[{"key":"2025041612132522500_CIT0001","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S0140-6736(17)33326-3","article-title":"Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries","volume":"391","author":"Allemani","year":"2018","journal-title":"Lancet"},{"key":"2025041612132522500_CIT0002","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1002\/cncr.28619","article-title":"Association between hypogonadism, symptom burden, and survival in male patients with advanced cancer","volume":"120","author":"Dev","year":"2014","journal-title":"Cancer"},{"key":"2025041612132522500_CIT0003","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1097\/MED.0000000000000583","article-title":"Hypogonadism and cancer survivorship","volume":"27","author":"Faw","year":"2020","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"2025041612132522500_CIT0004","doi-asserted-by":"publisher","first-page":"3975","DOI":"10.1210\/jc.2015-2236","article-title":"Treatment of symptoms of the menopause: an endocrine society clinical practice guideline","volume":"100","author":"Stuenkel","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"2025041612132522500_CIT0005","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.amjmed.2005.09.031","article-title":"Symptoms during the perimenopause: prevalence, severity, trajectory, and significance in women\u2019s lives","volume":"118","author":"Woods","year":"2005","journal-title":"Am J Med"},{"key":"2025041612132522500_CIT0006","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1097\/00042192-200310010-00013","article-title":"Hot flushes in a male population aged 55, 65, and 75 years, living in the community of Link\u00f6ping, Sweden","volume":"10","author":"Spetz","year":"2003","journal-title":"Menopause."},{"key":"2025041612132522500_CIT0007","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1001\/jamainternmed.2014.8063","article-title":"Duration of menopausal vasomotor symptoms over the menopause transition","volume":"175","author":"Avis","year":"2015","journal-title":"JAMA Intern Med"},{"key":"2025041612132522500_CIT0008","doi-asserted-by":"publisher","first-page":"4437","DOI":"10.1007\/s00520-022-06848-3","article-title":"Vasomotor symptoms in early breast cancer-a \u201creal world\u201d exploration of the patient experience","volume":"30","author":"Cole","year":"2022","journal-title":"Support Care Cancer"},{"key":"2025041612132522500_CIT0009","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"2025041612132522500_CIT0010","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1056\/NEJMoa1412379","article-title":"Adjuvant ovarian suppression in premenopausal breast cancer","volume":"372","author":"Francis","year":"2015","journal-title":"N Engl J Med"},{"key":"2025041612132522500_CIT0011","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/NEJM199811263392207","article-title":"Tamoxifen in the treatment of breast cancer","volume":"339","author":"Osborne","year":"1998","journal-title":"N Engl J Med"},{"key":"2025041612132522500_CIT0012","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1056\/NEJMoa032312","article-title":"A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer","volume":"349","author":"Goss","year":"2003","journal-title":"N Engl J Med"},{"key":"2025041612132522500_CIT0013","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s10549-020-05892-z","article-title":"Treatment interruption and discontinuation of hormonal therapy in hormone receptor-positive breast cancer patients","volume":"184","author":"Mao","year":"2020","journal-title":"Breast Cancer Res Treat"},{"key":"2025041612132522500_CIT0014","doi-asserted-by":"publisher","first-page":"e13729","DOI":"10.1111\/ecc.13729","article-title":"Adherence to adjuvant hormonal therapy in localised breast cancer","volume":"31","author":"Davies","year":"2022","journal-title":"Eur J Cancer Care (Engl)"},{"key":"2025041612132522500_CIT0015","doi-asserted-by":"publisher","first-page":"683","DOI":"10.6004\/jnccn.2021.7116","article-title":"Adjuvant hormone therapy-related hot flashes predict treatment discontinuation and worse breast cancer prognosis","volume":"20","author":"Zeng","year":"2022"},{"key":"2025041612132522500_CIT0016","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.breast.2022.04.010","article-title":"The impact of medication side effects on adherence and persistence to hormone therapy in breast cancer survivors: a quantitative systematic review","volume":"64","author":"Fleming","year":"2022","journal-title":"Breast"},{"key":"2025041612132522500_CIT0017","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/aja.2011.101","article-title":"Androgen deprivation therapy-associated vasomotor symptoms","volume":"14","author":"Jones","year":"2012","journal-title":"Asian J Androl"},{"key":"2025041612132522500_CIT0018","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/nrendo.2015.82","article-title":"Perimenopause as a neurological transition state","volume":"11","author":"Brinton","year":"2015","journal-title":"Nat Rev Endocrinol"},{"key":"2025041612132522500_CIT0019","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer","author":"Cornford","year":"2024","journal-title":"European Association of Urology"},{"key":"2025041612132522500_CIT0020","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1677\/jme.0.0250149","article-title":"Role of aromatase in sex steroid action","volume":"25","author":"Simpson","year":"2000","journal-title":"J Mol Endocrinol"},{"key":"2025041612132522500_CIT0021","first-page":"1319","article-title":"Management of hot flushes due to endocrine therapy for prostate carcinoma","volume":"10","author":"Smith","year":"1996","journal-title":"Oncology"},{"key":"2025041612132522500_CIT0022","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1177\/1557988306294162","article-title":"Physiology and endocrinology of hot flashes in prostate cancer","volume":"1","author":"Engstrom","year":"2007","journal-title":"Am J Mens Health"},{"key":"2025041612132522500_CIT0023","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.neuron.2018.02.022","article-title":"Regulation of body temperature by the nervous system","volume":"98","author":"Tan","year":"2018","journal-title":"Neuron"},{"key":"2025041612132522500_CIT0024","first-page":"1289","article-title":"Core temperature \u201cnull zone\u201d","volume":"71","author":"Mekjavi\u0107","year":"1991","journal-title":"J Appl Physiol Bethesda Md 1985"},{"key":"2025041612132522500_CIT0025","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/s0002-9378(99)70437-0","article-title":"Reduced thermoregulatory null zone in postmenopausal women with hot flashes","volume":"181","author":"Freedman","year":"1999","journal-title":"Am J Obstet Gynecol"},{"key":"2025041612132522500_CIT0026","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1210\/endo-128-5-2239","article-title":"Hypertrophy and increased gene expression of neurons containing neurokinin-B and substance-P messenger ribonucleic acids in the hypothalami of postmenopausal women","volume":"128","author":"Rance","year":"1991","journal-title":"Endocrinology"},{"key":"2025041612132522500_CIT0027","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.celrep.2018.06.037","article-title":"A neural circuit underlying the generation of hot flushes","volume":"24","author":"Padilla","year":"2018","journal-title":"Cell Rep"},{"key":"2025041612132522500_CIT0028","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1210\/en.2018-00934","article-title":"Glutamatergic neurokinin 3 receptor neurons in the median preoptic nucleus modulate heat-defense pathways in female mice","volume":"160","author":"Krajewski-Hall","year":"2019","journal-title":"Endocrinology"},{"key":"2025041612132522500_CIT0029","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/S0140-6736(08)60346-3","article-title":"Menopause","volume":"371","author":"Nelson","year":"2008","journal-title":"Lancet"},{"key":"2025041612132522500_CIT0030","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1093\/humupd\/dmi018","article-title":"Culture and symptom reporting at menopause","volume":"11","author":"Melby","year":"2005","journal-title":"Hum Reprod Update"},{"key":"2025041612132522500_CIT0031","doi-asserted-by":"publisher","first-page":"2354","DOI":"10.1210\/jcem.80.8.7629229","article-title":"Core body temperature and circadian rhythm of hot flashes in menopausal women","volume":"80","author":"Freedman","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"key":"2025041612132522500_CIT0032","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1097\/gme.0b013e3181cbb3c6","article-title":"Diurnal rhythm and concordance between objective and subjective hot flashes: the hilo women\u2019s health study","volume":"17","author":"Sievert","year":"2010","journal-title":"Menopause"},{"key":"2025041612132522500_CIT0033","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.maturitas.2011.10.003","article-title":"Are hot flashes associated with sleep disturbance during midlife? Results from the STRIDE cohort study","volume":"71","author":"Xu","year":"2012","journal-title":"Maturitas"},{"key":"2025041612132522500_CIT0034","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1089\/jwh.2021.0502","article-title":"Nocturnal hot flashes, but not serum hormone concentrations, as a predictor of insomnia in menopausal women: results from the midlife women\u2019s health study","volume":"32","author":"Hatcher","year":"2023"},{"key":"2025041612132522500_CIT0035","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/s0378-5122(97)83974-6","article-title":"Differential diagnosis of hot flashes","volume":"27","author":"Mohyi","year":"1997","journal-title":"Maturitas"},{"key":"2025041612132522500_CIT0036","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s11154-016-9394-8","article-title":"Flushing in (neuro)endocrinology","volume":"17","author":"Hannah-Shmouni","year":"2016","journal-title":"Rev Endocr Metab Disord"},{"key":"2025041612132522500_CIT0037","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1001\/jama.1959.03010300001001","article-title":"Contemporary therapy of the menopausal syndrome","volume":"171","author":"Kupperman","year":"1959","journal-title":"J Am Med Assoc"},{"key":"2025041612132522500_CIT0038","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/0022-3999(76)90005-2","article-title":"factor analytic study of climacteric symptoms","volume":"20","author":"Greene","year":"1976","journal-title":"J Psychosom Res"},{"key":"2025041612132522500_CIT0039","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/s0378-5122(98)00025-5","article-title":"Constructing a standard climacteric scale","volume":"29","author":"Greene","year":"1998","journal-title":"Maturitas"},{"key":"2025041612132522500_CIT0040","doi-asserted-by":"publisher","first-page":"59","DOI":"10.3109\/13697130009167600","article-title":"The Menopause Rating Scale (MRS): reliability of scores of menopausal complaints","volume":"3","author":"Schneider","year":"2000","journal-title":"Climacteric"},{"key":"2025041612132522500_CIT0041","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1111\/1471-0528.15990","article-title":"Variation in menopausal vasomotor symptoms outcomes in clinical trials: a systematic review","volume":"127","author":"Iliodromiti","year":"2020","journal-title":"BJOG"},{"key":"2025041612132522500_CIT0042","doi-asserted-by":"publisher","first-page":"4280","DOI":"10.1200\/JCO.2001.19.23.4280","article-title":"Methodologic lessons learned from hot flash studies","volume":"19","author":"Sloan","year":"2001","journal-title":"J Clin Oncol"},{"key":"2025041612132522500_CIT0043","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1016\/s0885-3924(01)00353-0","article-title":"The Hot Flash Related Daily Interference Scale: a tool for assessing the impact of hot flashes on quality of life following breast cancer","volume":"22","author":"Carpenter","year":"2001","journal-title":"J Pain Symptom Manage"},{"key":"2025041612132522500_CIT0044","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.breast.2016.02.013","article-title":"Hot flashes in breast cancer survivors: Frequency, severity and impact","volume":"27","author":"Chang","year":"2016","journal-title":"Breast"},{"key":"2025041612132522500_CIT0045","author":"Guidance for Industry","year":"2003","journal-title":"Estrogen and Estrogen\/Progestin Drug Products to Treat Vasomotor Symptoms and Vulvar and Vaginal Atrophy Symptoms \u2014 Recommendations for Clinical Evaluation"},{"issue":"6","key":"2025041612132522500_CIT0046","first-page":"573","article-title":"\u201cThe 2023 Nonhormone Therapy Position Statement of The North American Menopause Society\u201d Advisory Panel.\u00a0The 2023 nonhormone therapy position statement of The North American Menopause Society","volume":"30","year":"2023","journal-title":"Menopause N Y N"},{"key":"2025041612132522500_CIT0047","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1097\/GME.0000000000002028","article-title":"The 2022 hormone therapy position statement of The North American Menopause Society","volume":"29","author":"\u201cThe 2022 Hormone Therapy Position Statement of the North American Menopause Society\u201d Advisory Panel","year":"2022","journal-title":"Menopause N Y N"},{"key":"2025041612132522500_CIT0048","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.6004\/jnccn.2022.0052","article-title":"NCCN Guidelines\u00ae insights: survivorship, version 1.2022","volume":"20","author":"Sanft","year":"2022","journal-title":"JNCCN"},{"key":"2025041612132522500_CIT0049","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1007\/s00520-015-2967-3","article-title":"A randomised trial of the cool pad pillow topper versus standard care for sleep disturbance and hot flushes in women on endocrine therapy for breast cancer","volume":"24","author":"Marshall-McKenna","year":"2016","journal-title":"Support Care Cancer"},{"key":"2025041612132522500_CIT0050","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1080\/15402002.2019.1699100","article-title":"Thermal comfort intervention for hot-flash related insomnia symptoms in perimenopausal and postmenopausal-aged women: an exploratory study","volume":"19","author":"Composto","year":"2021","journal-title":"Behav Sleep Med"},{"key":"2025041612132522500_CIT0051","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/j.ajog.2005.04.001","article-title":"Body mass, estrogen levels, and hot flashes in midlife women","volume":"193","author":"Gallicchio","year":"2005","journal-title":"Am J Obstet Gynecol"},{"key":"2025041612132522500_CIT0052","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1097\/GME.0000000000000723","article-title":"Longitudinal analysis of changes in weight and waist circumference in relation to incident vasomotor symptoms: the Study of Women\u2019s Health Across the Nation (SWAN)","volume":"24","author":"Gold","year":"2017","journal-title":"Menopause"},{"key":"2025041612132522500_CIT0053","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1097\/GME.0000000000000884","article-title":"Does obesity increase the risk of hot flashes among midlife women?: a population-based study","volume":"24","author":"Saccomani","year":"2017","journal-title":"Menopause"},{"key":"2025041612132522500_CIT0054","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s10549-010-0802-6","article-title":"Weight gain is associated with increased risk of hot flashes in breast cancer survivors on aromatase inhibitors","volume":"124","author":"Su","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"2025041612132522500_CIT0055","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1200\/JCO.2011.36.8597","article-title":"Effect of postdiagnosis weight change on hot flash status among early-stage breast cancer survivors","volume":"30","author":"Caan","year":"2012","journal-title":"J Clin Oncol"},{"key":"2025041612132522500_CIT0056","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1097\/gme.0b013e31804b418c","article-title":"\u201cIt\u2019s my hormones, doctor\u201d--does physical activity help with menopausal symptoms","volume":"15","author":"van Poppel","year":"2008","journal-title":"Menopause N Y N"},{"key":"2025041612132522500_CIT0057","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1001\/archinternmed.2010.162","article-title":"An intensive behavioral weight loss intervention and hot flushes in women","volume":"170","author":"Huang","year":"2010","journal-title":"Arch Intern Med"},{"key":"2025041612132522500_CIT0058","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1097\/gme.0b013e31824f606e","article-title":"Effects of a dietary intervention and weight change on vasomotor symptoms in the Women\u2019s Health Initiative","volume":"19","author":"Kroenke","year":"2012","journal-title":"Menopause"},{"key":"2025041612132522500_CIT0059","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1097\/GME.0000000000000274","article-title":"Behavioral weight loss for the management of menopausal hot flashes: a pilot study","volume":"22","author":"Thurston","year":"2015","journal-title":"Menopause"},{"key":"2025041612132522500_CIT0060","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1097\/GME.0000000000002080","article-title":"A dietary intervention for vasomotor symptoms of menopause: a randomized, controlled trial","volume":"30","author":"Barnard","year":"2023","journal-title":"Menopause"},{"key":"2025041612132522500_CIT0061","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.maturitas.2005.01.008","article-title":"Factors associated with climacteric symptoms in women around menopause attending menopause clinics in Italy","volume":"52","author":"Di Donato","year":"2005","journal-title":"Maturitas"},{"key":"2025041612132522500_CIT0062","doi-asserted-by":"publisher","first-page":"CD006108","DOI":"10.1002\/14651858.CD006108.pub4","article-title":"Exercise for vasomotor menopausal symptoms","volume":"2014","author":"Daley","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"2025041612132522500_CIT0063","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1097\/AOG.0000000000000927","article-title":"Pooled analysis of six pharmacologic and nonpharmacologic interventions for vasomotor symptoms","volume":"126","author":"Guthrie","year":"2015","journal-title":"Obstet Gynecol"},{"key":"2025041612132522500_CIT0064","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1097\/GME.0000000000000651","article-title":"Effects of stretching on menopausal and depressive symptoms in middle-aged women: a randomized controlled trial","volume":"23","author":"Kai","year":"2016","journal-title":"Menopause"},{"key":"2025041612132522500_CIT0065","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.maturitas.2017.12.005","article-title":"Yoga for menopausal symptoms-a systematic review and meta-analysis","volume":"109","author":"Cramer","year":"2018","journal-title":"Maturitas"},{"key":"2025041612132522500_CIT0066","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1097\/GME.0000000000001947","article-title":"A 16-week multicomponent exercise training program improves menopause-related symptoms in middle-aged women. The FLAMENCO project randomized control trial","volume":"29","author":"Baena-Garc\u00eda","year":"2022","journal-title":"Menopause"},{"key":"2025041612132522500_CIT0067","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1080\/13697137.2021.1941849","article-title":"Effects of resistance training on quality of life in postmenopausal women with vasomotor symptoms","volume":"25","author":"Berin","year":"2022","journal-title":"Climacteric"},{"key":"2025041612132522500_CIT0068","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1111\/1471-0528.13193","article-title":"The effectiveness of exercise as treatment for vasomotor menopausal symptoms: randomised controlled trial","volume":"122","author":"Daley","year":"2015","journal-title":"BJOG"},{"key":"2025041612132522500_CIT0069","doi-asserted-by":"publisher","first-page":"797","DOI":"10.3109\/13697137.2015.1080236","article-title":"The association between hot flushes and smoking in midlife women: a meta-analysis","volume":"18","author":"Jenabi","year":"2015","journal-title":"Climacteric"},{"key":"2025041612132522500_CIT0070","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s40695-017-0024-8","article-title":"The Midlife Women\u2019s Health Study - a study protocol of a longitudinal prospective study on predictors of menopausal hot flashes","volume":"3","author":"Ziv-Gal","year":"2017","journal-title":"Womens Midlife Health"},{"key":"2025041612132522500_CIT0071","doi-asserted-by":"publisher","first-page":"478.e1","DOI":"10.1016\/j.ajog.2019.10.103","article-title":"Obesity, smoking, and risk of vasomotor menopausal symptoms: a pooled analysis of eight cohort studies","volume":"222","author":"Anderson","year":"2020","journal-title":"Am J Obstet Gynecol"},{"key":"2025041612132522500_CIT0072","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.maturitas.2015.06.029","article-title":"Does quitting smoking decrease the risk of midlife hot flashes? a longitudinal analysis","volume":"82","author":"Smith","year":"2015","journal-title":"Maturitas"},{"key":"2025041612132522500_CIT0073","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s10608-012-9476-1","article-title":"The efficacy of cognitive behavioral therapy: a review of meta-analyses","volume":"36","author":"Hofmann","year":"2012","journal-title":"Cognit Ther Res"},{"key":"2025041612132522500_CIT0074","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.jpsychores.2010.04.005","article-title":"A cognitive model of menopausal hot flushes and night sweats","volume":"69","author":"Hunter","year":"2010","journal-title":"J Psychosom Res"},{"key":"2025041612132522500_CIT0075","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1017\/S0033291721005407","article-title":"Efficacy of cognitive therapy and behavior therapy for menopausal symptoms: a systematic review and meta-analysis","volume":"52","author":"Ye","year":"2022","journal-title":"Psychol Med"},{"key":"2025041612132522500_CIT0076","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1200\/JCO.18.00655","article-title":"Efficacy of internet-based cognitive behavioral therapy for treatment-induced menopausal symptoms in breast cancer survivors: results of a randomized controlled trial","volume":"37","author":"Atema","year":"2019","journal-title":"J Clin Oncol"},{"key":"2025041612132522500_CIT0077","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1097\/gme.0b013e31823fe835","article-title":"Effectiveness of group and self-help cognitive behavior therapy in reducing problematic menopausal hot flushes and night sweats (MENOS 2): a randomized controlled trial","volume":"19","author":"Ayers","year":"2012","journal-title":"Menopause"},{"issue":"10","key":"2025041612132522500_CIT0078","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1002\/pon.5432","article-title":"Effectiveness of nurse-led group CBT for hot flushes and night sweats in women with breast cancer: Results of the MENOS4 randomised controlled trial.","volume":"29","author":"Fenlon","year":"2020","journal-title":"Psychooncology"},{"key":"2025041612132522500_CIT0079","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.annonc.2020.09.010","article-title":"5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)","volume":"31","author":"Cardoso","year":"2020","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"2025041612132522500_CIT0080","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1007\/s11864-023-01168-y","article-title":"Hypnosis for symptom management in adult cancer patients: what is the evidence","volume":"25","author":"Vayne-Bossert","year":"2024","journal-title":"Curr Treat Options Oncol"},{"key":"2025041612132522500_CIT0081","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s11912-018-0739-1","article-title":"The role of hypnosis in cancer care","volume":"20","author":"Carlson","year":"2018","journal-title":"Curr Oncol Rep"},{"key":"2025041612132522500_CIT0082","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1097\/gme.0b013e31826ce3ed","article-title":"Clinical hypnosis in the treatment of postmenopausal hot flashes: a randomized controlled trial","volume":"20","author":"Elkins","year":"2013","journal-title":"Menopause"},{"key":"2025041612132522500_CIT0083","doi-asserted-by":"publisher","first-page":"5022","DOI":"10.1200\/JCO.2008.16.6389","article-title":"Randomized trial of a hypnosis intervention for treatment of hot flashes among breast cancer survivors","volume":"26","author":"Elkins","year":"2008","journal-title":"J Clin Oncol"},{"key":"2025041612132522500_CIT0084","article-title":"Stellate Ganglion Blocks","volume-title":"StatPearls","author":"Piraccini","year":"2023"},{"key":"2025041612132522500_CIT0085","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1136\/rapm-2018-100127","article-title":"Complications associated with stellate ganglion nerve block: a systematic review","volume":"44","author":"Goel","year":"2019","journal-title":"Reg Anesth Pain Med"},{"key":"2025041612132522500_CIT0086","doi-asserted-by":"publisher","first-page":"147","DOI":"10.3949\/ccjm.89a.21032","article-title":"Stellate ganglion block as a treatment for vasomotor symptoms: clinical application","volume":"89","author":"Lee","year":"2022","journal-title":"Cleve Clin J Med"},{"key":"2025041612132522500_CIT0087","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1097\/GME.0000000000000194","article-title":"Effects of stellate ganglion block on vasomotor symptoms: findings from a randomized controlled clinical trial in postmenopausal women","volume":"21","author":"Walega","year":"2014","journal-title":"Menopause"},{"key":"2025041612132522500_CIT0088","article-title":"Acupuncture","volume-title":"StatPearls","author":"Van Hal","year":"2023"},{"key":"2025041612132522500_CIT0089","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.hoc.2008.04.005","article-title":"The value of acupuncture in cancer care","volume":"22","author":"Lu","year":"2008","journal-title":"Hematol Oncol Clin North Am"},{"key":"2025041612132522500_CIT0090","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1097\/GME.0000000000000597","article-title":"Acupuncture in Menopause (AIM) study: a pragmatic, randomized controlled trial","volume":"23","author":"Avis","year":"2016","journal-title":"Menopause"},{"key":"2025041612132522500_CIT0091","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1200\/JCO.2015.63.2893","article-title":"Acupuncture as an integrative approach for the treatment of hot flashes in women with breast cancer: a prospective multicenter randomized controlled trial (AcCliMaT)","volume":"34","author":"Lesi","year":"2016","journal-title":"J Clin Oncol"},{"key":"2025041612132522500_CIT0092","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1097\/GME.0000000000000260","article-title":"Effects of acupuncture on menopause-related symptoms and quality of life in women in natural menopause: a meta-analysis of randomized controlled trials","volume":"22","author":"Chiu","year":"2015","journal-title":"Menopause"},{"key":"2025041612132522500_CIT0093","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1097\/GME.0000000000000735","article-title":"Trajectories of response to acupuncture for menopausal vasomotor symptoms: the Acupuncture in Menopause study","volume":"24","author":"Avis","year":"2017","journal-title":"Menopause"},{"key":"2025041612132522500_CIT0094","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s12906-021-03208-2","article-title":"Factors associated with a clinically relevant reduction in menopausal symptoms of a standardized acupuncture approach for women with bothersome menopausal symptoms","volume":"21","author":"Waldorff","year":"2021","journal-title":"BMC Complement Med Ther"},{"key":"2025041612132522500_CIT0095","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1097\/GME.0000000000001651","article-title":"Acupuncture ameliorated vasomotor symptoms during menopausal transition: single-blind, placebo-controlled, randomized trial to test treatment efficacy","volume":"28","author":"Soares","year":"2020","journal-title":"Menopause"},{"key":"2025041612132522500_CIT0096","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1007\/s10549-010-1283-3","article-title":"Reducing vasomotor symptoms with acupuncture in breast cancer patients treated with adjuvant tamoxifen: a randomized controlled trial","volume":"135","author":"Liljegren","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"2025041612132522500_CIT0097","doi-asserted-by":"publisher","first-page":"CD007410","DOI":"10.1002\/14651858.CD007410.pub2","article-title":"Acupuncture for menopausal hot flushes","volume":"2013","author":"Dodin","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"2025041612132522500_CIT0098","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1016\/j.mehy.2004.11.046","article-title":"Isoflavones made simple - genistein\u2019s agonist activity for the beta-type estrogen receptor mediates their health benefits","volume":"66","author":"McCarty","year":"2006","journal-title":"Med Hypotheses"},{"key":"2025041612132522500_CIT0099","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1016\/j.ejca.2008.05.019","article-title":"Do phytoestrogens reduce the risk of breast cancer and breast cancer recurrence? What clinicians need to know","volume":"44","author":"Velentzis","year":"2008","journal-title":"Eur J Cancer"},{"key":"2025041612132522500_CIT0100","doi-asserted-by":"publisher","first-page":"2554","DOI":"10.1001\/jama.2016.8012","article-title":"Use of plant-based therapies and menopausal symptoms: a systematic review and meta-analysis","volume":"315","author":"Franco","year":"2016","journal-title":"JAMA"},{"key":"2025041612132522500_CIT0101","doi-asserted-by":"publisher","first-page":"CD001395","DOI":"10.1002\/14651858.CD001395.pub4","article-title":"Phytoestrogens for menopausal vasomotor symptoms","volume":"2013","author":"Lethaby","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"2025041612132522500_CIT0102","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1038\/s41430-019-0398-9","article-title":"Soy intake and vasomotor menopausal symptoms among midlife women: a pooled analysis of five studies from the InterLACE consortium","volume":"73","author":"Dunneram","year":"2019","journal-title":"Eur J Clin Nutr"},{"key":"2025041612132522500_CIT0103","doi-asserted-by":"publisher","first-page":"dju189","DOI":"10.1093\/jnci\/dju189","article-title":"The effects of soy supplementation on gene expression in breast cancer: a randomized placebo-controlled study","volume":"106","author":"Shike","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"2025041612132522500_CIT0104","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1002\/ijc.34321","article-title":"Postdiagnosis dietary factors, supplement use and breast cancer prognosis: Global Cancer Update Programme (CUP Global) systematic literature review and meta-analysis","volume":"152","author":"Becerra-Tom\u00e1s","year":"2023","journal-title":"Int J Cancer"},{"key":"2025041612132522500_CIT0105","doi-asserted-by":"publisher","first-page":"100350","DOI":"10.1016\/j.ctarc.2021.100350","article-title":"Pre-diagnosis and early post-diagnosis dietary soy isoflavone intake and survival outcomes: a prospective cohort study of early stage breast cancer survivors","volume":"27","author":"Ho","year":"2021","journal-title":"Cancer Treat Res Commun"},{"key":"2025041612132522500_CIT0106","article-title":"Black Cohosh (PDQ\u00ae): Health Professional Version","volume-title":"PDQ Cancer Information Summaries","author":"PDQ Integrative, Alternative, and Complementary Therapies Editorial Board","year":"2002"},{"key":"2025041612132522500_CIT0107","doi-asserted-by":"publisher","first-page":"CD007244","DOI":"10.1002\/14651858.CD007244.pub2","article-title":"Black cohosh (Cimicifuga spp.) for menopausal symptoms","volume":"2012","author":"Leach","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"2025041612132522500_CIT0108","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1097\/gme.0b013e31816054bf","article-title":"United States pharmacopeia review of the black cohosh case reports of hepatotoxicity","volume":"15","author":"Mahady","year":"2008","journal-title":"Menopause N Y N"},{"key":"2025041612132522500_CIT0109","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1177\/1534735413477191","article-title":"Black cohosh and breast cancer: a systematic review","volume":"13","author":"Fritz","year":"2014","journal-title":"Integr Cancer Ther"},{"key":"2025041612132522500_CIT0110","doi-asserted-by":"publisher","first-page":"15347354221137290","DOI":"10.1177\/15347354221137290","article-title":"The effect of black cohosh on Ki67 expression and tumor volume: a pilot study of ductal carcinoma in situ patients","volume":"21","author":"Trant","year":"2022","journal-title":"Integr Cancer Ther"},{"key":"2025041612132522500_CIT0111","doi-asserted-by":"publisher","first-page":"447","DOI":"10.7326\/0003-4819-85-4-447","article-title":"Menopause and risk of cardiovascular disease: the Framingham study","volume":"85","author":"Kannel","year":"1976","journal-title":"Ann Intern Med"},{"key":"2025041612132522500_CIT0112","doi-asserted-by":"publisher","first-page":"CD002978","DOI":"10.1002\/14651858.CD002978.pub2","article-title":"Oral oestrogen and combined oestrogen\/progestogen therapy versus placebo for hot flushes","volume":"2004","author":"Maclennan","year":"2004","journal-title":"Cochrane Database Syst Rev"},{"key":"2025041612132522500_CIT0113","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1001\/jama.288.3.321","article-title":"Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women\u2019s Health Initiative randomized controlled trial","volume":"288","author":"Rossouw","year":"2002","journal-title":"JAMA"},{"key":"2025041612132522500_CIT0114","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/S0140-6736(19)31709-X","article-title":"Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence","volume":"394","author":"Collaborative Group on Hormonal Factors in Breast Cancer","year":"2019","journal-title":"Lancet Lond Engl"},{"key":"2025041612132522500_CIT0115","first-page":"l162","article-title":"Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases","volume":"364","author":"Vinogradova","year":"2019","journal-title":"BMJ"},{"key":"2025041612132522500_CIT0116","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1097\/01.AOG.0000428645.90795.d9","article-title":"Committee on Gynecologic Practice.\u00a0ACOG committee opinion no. 556: Postmenopausal estrogen therapy: route of administration and risk of venous thromboembolism","volume":"121","year":"2013","journal-title":"Obstet Gynecol"},{"key":"2025041612132522500_CIT0117","year":"2006"},{"key":"2025041612132522500_CIT0118","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.maturitas.2005.02.011","article-title":"International tibolone consensus group. tibolone: clinical recommendations and practical guidelines. a report of the international tibolone consensus group","volume":"51","author":"Kenemans","year":"2005","journal-title":"Maturitas"},{"key":"2025041612132522500_CIT0119","doi-asserted-by":"publisher","first-page":"CD008536","DOI":"10.1002\/14651858.CD008536.pub3","article-title":"Short-term and long-term effects of tibolone in postmenopausal women","volume":"10","author":"Formoso","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"2025041612132522500_CIT0120","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/S1470-2045(08)70341-3","article-title":"Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial","volume":"10","author":"Kenemans","year":"2009","journal-title":"Lancet Oncol"},{"key":"2025041612132522500_CIT0121","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1097\/AOG.0000000000004601","article-title":"The American College of Obstetricians and Gynecologists.\u00a0Treatment of urogenital symptoms in individuals with a history of estrogen-dependent breast cancer: clinical consensus","volume":"138","year":"2021","journal-title":"Obstet Gynecol"},{"key":"2025041612132522500_CIT0122","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.juro.2018.03.115","article-title":"Evaluation and management of testosterone deficiency: AUA Guideline","volume":"200","author":"Mulhall","year":"2018","journal-title":"J Urol"},{"key":"2025041612132522500_CIT0123","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1002\/(SICI)1097-0142(19980501)82:9<1789::AID-CNCR27>3.0.CO;2-#","article-title":"Long term use of megestrol acetate by cancer survivors for the treatment of hot flashes","volume":"82","author":"Quella","year":"1998","journal-title":"Cancer"},{"key":"2025041612132522500_CIT0124","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1200\/JCO.2005.04.7324","article-title":"Phase III comparison of depomedroxyprogesterone acetate to venlafaxine for managing hot flashes: North Central Cancer Treatment Group Trial N99C7","volume":"24","author":"Loprinzi","year":"2006","journal-title":"J Clin Oncol"},{"key":"2025041612132522500_CIT0125","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/S1470-2045(09)70338-9","article-title":"Efficacy of venlafaxine, medroxyprogesterone acetate, and cyproterone acetate for the treatment of vasomotor hot flushes in men taking gonadotropin-releasing hormone analogues for prostate cancer: a double-blind, randomised trial","volume":"11","author":"Irani","year":"2010","journal-title":"Lancet Oncol"},{"key":"2025041612132522500_CIT0126","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1093\/jnci\/djn058","article-title":"Increased risk of recurrence after hormone replacement therapy in breast cancer survivors","volume":"100","author":"Holmberg","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"2025041612132522500_CIT0127","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.ejca.2012.07.003","article-title":"Hormone replacement therapy after breast cancer: 10 year follow up of the Stockholm randomised trial","volume":"49","author":"Fahl\u00e9n","year":"2013","journal-title":"Eur J Cancer"},{"key":"2025041612132522500_CIT0128","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.breast.2018.05.002","article-title":"The oncologic impact of hormone replacement therapy in premenopausal breast cancer survivors: a systematic review","volume":"40","author":"Wang","year":"2018","journal-title":"Breast"},{"key":"2025041612132522500_CIT0129","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.breast.2019.06.002","article-title":"Safety of menopausal hormone therapy in breast cancer survivors older than fifty at diagnosis: a systematic review and meta-analysis","volume":"47","author":"Mudhune","year":"2019","journal-title":"Breast"},{"key":"2025041612132522500_CIT0130","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s10549-021-06436-9","article-title":"Safety of systemic hormone replacement therapy in breast cancer survivors: a systematic review and meta-analysis","volume":"191","author":"Poggio","year":"2022","journal-title":"Breast Cancer Res Treat"},{"key":"2025041612132522500_CIT0131","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1200\/JCO.2015.64.3809","article-title":"American Cancer Society\/American Society of clinical oncology breast cancer survivorship care guideline","volume":"34","author":"Runowicz","year":"2016","journal-title":"J Clin Oncol"},{"key":"2025041612132522500_CIT0132","doi-asserted-by":"publisher","first-page":"CD008830","DOI":"10.1002\/14651858.CD008830.pub3","article-title":"Hormone replacement therapy for women previously treated for endometrial cancer","volume":"5","author":"Edey","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"2025041612132522500_CIT0133","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1097\/GME.0000000000000508","article-title":"Hormone therapy for ovarian cancer survivors: systematic review and meta-analysis","volume":"23","author":"Pergialiotis","year":"2016","journal-title":"Menopause"},{"key":"2025041612132522500_CIT0134","doi-asserted-by":"publisher","first-page":"356","DOI":"10.3390\/cancers15020356","article-title":"Impact of hormone replacement therapy on the overall survival and progression free survival of ovarian cancer patients: a systematic review and meta-analysis","volume":"15","author":"Achima\u0219-Cadariu","year":"2023","journal-title":"Cancers"},{"key":"2025041612132522500_CIT0135","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1111\/andr.13299","article-title":"Testosterone replacement in prostate cancer survivors with testosterone deficiency: study protocol of a randomized controlled trial","volume":"11","author":"Valderr\u00e1bano","year":"2023","journal-title":"Andrology"},{"key":"2025041612132522500_CIT0136","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJM199408113310602","article-title":"Megestrol acetate for the prevention of hot flashes","volume":"331","author":"Loprinzi","year":"1994","journal-title":"N Engl J Med"},{"key":"2025041612132522500_CIT0137","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1097\/00007611-199904000-00013","article-title":"Progressive prostate cancer associated with use of megestrol acetate administered for control of hot flashes","volume":"92","author":"Sartor","year":"1999","journal-title":"South Med J"},{"key":"2025041612132522500_CIT0138","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1210\/jc.2018-00229","article-title":"Testosterone therapy in men with hypogonadism: An Endocrine Society Clinical Practice Guideline","volume":"103","author":"Bhasin","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"2025041612132522500_CIT0139","author":"Salonia","year":"2024"},{"key":"2025041612132522500_CIT0140","doi-asserted-by":"publisher","first-page":"E416","DOI":"10.5489\/cuaj.8054","article-title":"UPDATE - Canadian Urological Association guideline on androgen deprivation therapy: adverse events and management strategies","volume":"16","author":"Kokorovic","year":"2022","journal-title":"Can Urol Assoc J"},{"key":"2025041612132522500_CIT0141","doi-asserted-by":"publisher","first-page":"2761","DOI":"10.1210\/jc.2018-01175","article-title":"Hypothalamic-pituitary and growth disorders in survivors of childhood cancer: an endocrine society clinical practice guideline","volume":"103","author":"Sklar","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"2025041612132522500_CIT0142","doi-asserted-by":"publisher","first-page":"e1001275","DOI":"10.1371\/journal.pmed.1001275","article-title":"Risk of venous thromboembolism in patients with cancer: a systematic review and meta-analysis","volume":"9","author":"Horsted","year":"2012","journal-title":"PLoS Med"},{"key":"2025041612132522500_CIT0143","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/S0140-6736(19)31674-5","article-title":"Medium and long-term risks of specific cardiovascular diseases in survivors of 20 adult cancers: a population-based cohort study using multiple linked UK electronic health records databases","volume":"394","author":"Strongman","year":"2019","journal-title":"Lancet"},{"key":"2025041612132522500_CIT0144","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jacc.2022.04.042","article-title":"Cardiovascular disease risk among cancer survivors: the Atherosclerosis Risk in Communities (ARIC) study","volume":"80","author":"Florido","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2025041612132522500_CIT0145","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1093\/jnci\/dji290","article-title":"Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma","volume":"97","author":"Travis","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"2025041612132522500_CIT0146","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1007\/s10549-012-1993-9","article-title":"Breast cancer phenotype in women with TP53 germline mutations: a Li-Fraumeni syndrome consortium effort","volume":"133","author":"Masciari","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"2025041612132522500_CIT0147","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1001\/jama.2017.7112","article-title":"Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers","volume":"317","author":"Kuchenbaecker","year":"2017","journal-title":"JAMA"},{"key":"2025041612132522500_CIT0148","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1001\/jamaoncol.2018.0211","article-title":"Hormone replacement therapy after oophorectomy and breast cancer risk among BRCA1 mutation carriers","volume":"4","author":"Kotsopoulos","year":"2018","journal-title":"JAMA Oncol"},{"key":"2025041612132522500_CIT0149","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1007\/s00432-021-03629-z","article-title":"Hormone replacement therapy in BRCA mutation carriers and risk of ovarian, endometrial, and breast cancer: a systematic review","volume":"147","author":"Huber","year":"2021","journal-title":"J Cancer Res Clin Oncol"},{"key":"2025041612132522500_CIT0150","author":"National Cancer Institute"},{"key":"2025041612132522500_CIT0151","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1097\/GME.0000000000001895","article-title":"Factors associated with high placebo response in clinical studies of hot flashes: a meta-analysis","volume":"29","author":"Miyazaki","year":"2021","journal-title":"Menopause"},{"key":"2025041612132522500_CIT0152","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.psym.2014.01.010","article-title":"Antidepressants and the risk of hyponatremia: a class-by-class review of literature","volume":"55","author":"De Picker","year":"2014","journal-title":"Psychosomatics"},{"key":"2025041612132522500_CIT0153","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1634\/theoncologist.2011-0400","article-title":"Diagnosis and management of hyponatremia in cancer patients","volume":"17","author":"Castillo","year":"2012","journal-title":"Oncologist"},{"key":"2025041612132522500_CIT0154","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1097\/YIC.0000000000000023","article-title":"A comparative review of escitalopram, paroxetine, and sertraline: are they all alike","volume":"29","author":"Sanchez","year":"2014","journal-title":"Int Clin Psychopharmacol"},{"key":"2025041612132522500_CIT0155","doi-asserted-by":"publisher","first-page":"409","DOI":"10.31887\/DCNS.2008.10.4\/kkelly","article-title":"Toward achieving optimal response: understanding and managing antidepressant side effects","volume":"10","author":"Kelly","year":"2008","journal-title":"Dialogues Clin Neurosci"},{"key":"2025041612132522500_CIT0156","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1093\/jnci\/djg108","article-title":"Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine","volume":"95","author":"Stearns","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"2025041612132522500_CIT0157","doi-asserted-by":"publisher","first-page":"2781","DOI":"10.2147\/NDT.S141832","article-title":"A meta-analysis of effects of selective serotonin reuptake inhibitors on blood pressure in depression treatment: outcomes from placebo and serotonin and noradrenaline reuptake inhibitor controlled trials","volume":"13","author":"Zhong","year":"2017","journal-title":"Neuropsychiatr Dis Treat"},{"key":"2025041612132522500_CIT0158","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1345\/aph.1G293","article-title":"Hyponatremia associated with selective serotonin-reuptake inhibitors in older adults","volume":"40","author":"Jacob","year":"2006","journal-title":"Ann Pharmacother"},{"key":"2025041612132522500_CIT0159","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.jad.2019.02.060","article-title":"Association between citalopram, escitalopram and QTc prolongation in a real-world geriatric setting","volume":"250","author":"Cr\u00e9peau-Gendron","year":"2019","journal-title":"J Affect Disord"},{"key":"2025041612132522500_CIT0160","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1007\/s40264-022-01246-4","article-title":"Withdrawal syndrome following discontinuation of 28 antidepressants: pharmacovigilance analysis of 31,688 reports from the WHO SPONTANEOUS REPORTING DATABASE","volume":"45","author":"Gastaldon","year":"2022","journal-title":"Drug Saf"},{"key":"2025041612132522500_CIT0161","author":"Venlafaxine: Drug information","year":"2023"},{"key":"2025041612132522500_CIT0162","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.1016\/j.jpainsymman.2009.05.003","article-title":"Pharmacological management of neuropathic pain in older adults: an update on peripherally and centrally acting agents","volume":"38","author":"McGeeney","year":"2009","journal-title":"J Pain Symptom Manage"},{"key":"2025041612132522500_CIT0163","first-page":"399","article-title":"Clonidine-induced bradycardia","volume":"41","author":"Golusinski","year":"1995","journal-title":"J Fam Pract"},{"key":"2025041612132522500_CIT0164","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s40360-018-0198-1","article-title":"A case report of clonidine induced syncope: a review of central actions of an old cardiovascular drug","volume":"19","author":"Sandweiss","year":"2018","journal-title":"BMC Pharmacol Toxicol"},{"key":"2025041612132522500_CIT0165","author":"Clonidine: Drug information","year":"2023"},{"key":"2025041612132522500_CIT0166","first-page":"11","article-title":"Anticholinergic effects of medication in elderly patients","volume":"62","author":"Tune","year":"2001","journal-title":"J Clin Psychiatry"},{"key":"2025041612132522500_CIT0167","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/S0140-6736(23)00085-5","article-title":"Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study","volume":"401","author":"Lederman","year":"2023","journal-title":"Lancet"},{"key":"2025041612132522500_CIT0168","author":"US Food and Drug Administration","year":"2024","journal-title":"FDA Adds Warning About Rare Occurrence of Serious Liver Injury with Use of Veozah (fezolinetant) for Hot Flashes Due to Menopause. Stop Medicine if Signs and Symptoms of Liver Injury Occur - Drug Safety Communication"},{"key":"2025041612132522500_CIT0169","volume-title":"Veozah (fezolinetant) [Prescribing Information]","year":"2023"},{"key":"2025041612132522500_CIT0170","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1001\/jama.2010.2016","article-title":"Efficacy of escitalopram for hot flashes in healthy menopausal women: a randomized controlled trial","volume":"305","author":"Freeman","year":"2011","journal-title":"JAMA"},{"key":"2025041612132522500_CIT0171","doi-asserted-by":"publisher","first-page":"2827","DOI":"10.1001\/jama.289.21.2827","article-title":"Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial","volume":"289","author":"Stearns","year":"2003","journal-title":"JAMA"},{"key":"2025041612132522500_CIT0172","doi-asserted-by":"publisher","first-page":"6919","DOI":"10.1200\/jco.2005.10.081","article-title":"Paroxetine is an effective treatment for hot flashes: results from a prospective randomized clinical trial","volume":"23","author":"Stearns","year":"2005","journal-title":"J Clin Oncol"},{"key":"2025041612132522500_CIT0173","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1016\/S0140-6736(00)03403-6","article-title":"Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial","volume":"356","author":"Loprinzi","year":"2000","journal-title":"Lancet"},{"key":"2025041612132522500_CIT0174","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s10549-008-0138-7","article-title":"Venlafaxine versus clonidine for the treatment of hot flashes in breast cancer patients: a double-blind, randomized cross-over study","volume":"115","author":"Buijs","year":"2009","journal-title":"Breast Cancer Res Treat"},{"key":"2025041612132522500_CIT0175","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1056\/NEJMp1402080","article-title":"FDA approval of paroxetine for menopausal hot flushes","volume":"370","author":"Orleans","year":"2014","journal-title":"N Engl J Med"},{"key":"2025041612132522500_CIT0176","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.ygyno.2016.10.006","article-title":"Role of paroxetine in the management of hot flashes in gynecological cancer survivors: results of the first randomized single-center controlled trial","volume":"143","author":"Capriglione","year":"2016","journal-title":"Gynecol Oncol"},{"key":"2025041612132522500_CIT0177","author":"US Food and Drug Administration","year":"2012","journal-title":"FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses"},{"issue":"2","key":"2025041612132522500_CIT0178","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.psym.2017.10.009","article-title":"QT prolongation, torsades de pointes, and psychotropic medications: a 5-year update","volume":"59","author":"Beach","year":"2018","journal-title":"Psychosomatics"},{"key":"2025041612132522500_CIT0179","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1001\/jama.2022.24140","article-title":"Management of menopausal symptoms: a review","volume":"329","author":"Crandall","year":"2023","journal-title":"JAMA"},{"key":"2025041612132522500_CIT0180","doi-asserted-by":"publisher","first-page":"141","DOI":"10.2147\/DHPS.S7634","article-title":"Antidepressant-associated sexual dysfunction: impact, effects, and treatment","volume":"2","author":"Higgins","year":"2010","journal-title":"Drug Healthc Patient Saf"},{"key":"2025041612132522500_CIT0181","first-page":"37","article-title":"Weight gain and antidepressants","volume":"61","author":"Fava","year":"2000","journal-title":"J Clin Psychiatry"},{"key":"2025041612132522500_CIT0182","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/S0140-6736(05)67215-7","article-title":"Gabapentin for hot flashes in 420 women with breast cancer: a randomised double-blind placebo-controlled trial","volume":"366","author":"Pandya","year":"2005","journal-title":"Lancet"},{"key":"2025041612132522500_CIT0183","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1200\/JCO.2009.24.5647","article-title":"Phase III, randomized, double-blind, placebo-controlled evaluation of pregabalin for alleviating hot flashes, N07C1","volume":"28","author":"Loprinzi","year":"2010","journal-title":"J Clin Oncol"},{"key":"2025041612132522500_CIT0184","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s10549-012-2251-x","article-title":"A randomized, controlled, double-blinded clinical trial of gabapentin 300 versus 900\u00a0mg versus placebo for anxiety symptoms in breast cancer survivors","volume":"136","author":"Lavigne","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"2025041612132522500_CIT0185","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1210\/jc.2014-3421","article-title":"Clinical review: drugs commonly associated with weight change: a systematic review and meta-analysis","volume":"100","author":"Domecq","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"2025041612132522500_CIT0186","first-page":"583","article-title":"Effect of clonidine on hot flashes in postmenopausal women","volume":"60","author":"Laufer","year":"1982","journal-title":"Obstet Gynecol"},{"key":"2025041612132522500_CIT0187","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/0002-9378(87)90050-0","article-title":"Treatment of menopausal hot flashes with transdermal administration of clonidine","volume":"156","author":"Nagamani","year":"1987","journal-title":"Am J Obstet Gynecol"},{"key":"2025041612132522500_CIT0188","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1200\/JCO.1994.12.1.155","article-title":"Transdermal clonidine for ameliorating tamoxifen-induced hot flashes","volume":"12","author":"Goldberg","year":"1994","journal-title":"J Clin Oncol"},{"key":"2025041612132522500_CIT0189","doi-asserted-by":"publisher","first-page":"788","DOI":"10.7326\/0003-4819-132-10-200005160-00004","article-title":"Oral clonidine in postmenopausal patients with breast cancer experiencing tamoxifen-induced hot flashes: a University of Rochester Cancer Center Community Clinical Oncology Program study","volume":"132","author":"Pandya","year":"2000","journal-title":"Ann Intern Med"},{"key":"2025041612132522500_CIT0190","doi-asserted-by":"publisher","first-page":"3862","DOI":"10.1200\/JCO.2010.33.1298","article-title":"Management of hot flashes in patients who have breast cancer with venlafaxine and clonidine: a randomized, double-blind, placebo-controlled trial","volume":"29","author":"Boekhout","year":"2011","journal-title":"J Clin Oncol"},{"key":"2025041612132522500_CIT0191","doi-asserted-by":"publisher","first-page":"pkz088","DOI":"10.1093\/jncics\/pkz088","article-title":"Oxybutynin vs placebo for hot flashes in women with or without breast cancer: a randomized, double-blind clinical trial (ACCRU SC-1603)","volume":"4","author":"Leon-Ferre","year":"2020","journal-title":"JNCI Cancer Spectr"},{"key":"2025041612132522500_CIT0192","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1002\/nau.24827","article-title":"The risk of delirium and falls or fractures with the use of overactive bladder anticholinergic medications","volume":"41","author":"Welk","year":"2022","journal-title":"Neurourol Urodyn"},{"key":"2025041612132522500_CIT0193","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1097\/gme.0000000000000773","article-title":"Extended-release oxybutynin therapy for vasomotor symptoms in women: a randomized clinical trial","volume":"23","author":"Simon","year":"2016","journal-title":"Menopause N Y N"},{"key":"2025041612132522500_CIT0194","author":"FDA Approves Novel Drug to Treat Moderate to Severe Hot Flashes Caused by Menopause","year":"2023"},{"key":"2025041612132522500_CIT0195","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1097\/GME.0000000000002281","article-title":"Systematic review and network meta-analysis comparing the efficacy of fezolinetant with hormone and nonhormone therapies for treatment of vasomotor symptoms due to menopause","volume":"31","author":"Morga","year":"2024","journal-title":"Menopause"},{"key":"2025041612132522500_CIT0196","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1097\/GME.0000000000002340","article-title":"Fezolinetant treatment of moderate-to-severe vasomotor symptoms due to menopause: effect of intrinsic and extrinsic factors in two phase 3 studies (SKYLIGHT 1 and 2)","volume":"31","author":"Santoro","year":"2024","journal-title":"Menopause"},{"key":"2025041612132522500_CIT0197","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1097\/AOG.0000000000005114","article-title":"Safety of fezolinetant for vasomotor symptoms associated with menopause: a randomized controlled trial","volume":"141","author":"Neal-Perry","year":"2023","journal-title":"Obstet Gynecol"},{"key":"2025041612132522500_CIT0198","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1210\/clinem\/dgad058","article-title":"Efficacy and safety of fezolinetant in moderate to severe vasomotor symptoms associated with menopause: a phase 3 RCT","volume":"108","author":"Johnson","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"2025041612132522500_CIT0199","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1097\/GME.0000000000002138","article-title":"Efficacy and safety of elinzanetant, a selective neurokinin-1,3 receptor antagonist for vasomotor symptoms: a dose-finding clinical trial (SWITCH-1)","volume":"30","author":"Simon","year":"2023","journal-title":"Menopause."},{"key":"2025041612132522500_CIT0200","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1016\/S0140-6736(22)01977-8","article-title":"Q-122 as a novel, non-hormonal, oral treatment for vasomotor symptoms in women taking tamoxifen or an aromatase inhibitor after breast cancer: a phase 2, randomised, double-blind, placebo-controlled trial","volume":"400","author":"Vrselja","year":"2022","journal-title":"Lancet."}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/2\/oyaf002\/62261623\/oyaf002.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/2\/oyaf002\/62261623\/oyaf002.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T16:13:52Z","timestamp":1744820032000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyaf002\/8051413"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":200,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2,6]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyaf002","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,2]]},"published":{"date-parts":[[2025,2]]},"article-number":"oyaf002"}}